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It is now commonly accepted that inflam­
mation contributes to the initiation, promo­
tion, and progression of tumor development.   
Although it has long been speculated that in­
flammation is associated with cancer, the un­
derlying mechanisms have been elusive and are 
only now beginning to be defined (Coussens 
and Werb, 2002). One of the best clinically 
characterized examples of the association be­
tween inflammation and carcinogenesis is the 
development of colon cancer in patients suffer­
ing from ulcerative colitis (UC), which is a 
common form of inflammatory bowel disease 
(IBD). UC affects 1 person per 600 in the 
US, and it is defined by characteristic ulcers 
observed in the colon. Patients suffering from 
UC demonstrate a significantly increased risk 
of colorectal cancer (CRC), which seems to be 
associated with both the duration of the disease 
and the degree of mucosal inflammation (Eaden 
et al., 2001). CRC is the third most common 
form of cancer in the Western hemisphere and 
accounts for 655,000 deaths per year world­
wide. A common denominator for both UC 
and colon cancer is the activation of pathways 
associated with inflammation.
Two families of innate immune receptors, 
the Toll­like receptors (TLRs) and the nu­
cleotide­binding domain, leucine­rich­repeat­ 
containing (NLR) proteins, have emerged as 
essential mediators of gastrointestinal inflam­
mation and homeostasis (Akira et al., 2006; 
Franchi et al., 2006). The NLRs mediate host 
immune response to a myriad of pathogen­ 
associated molecular patterns, including bacteria, 
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Colitis-associated cancer (CAC) is a major complication of inflammatory bowel diseases.  
We show that components of the inflammasome are protective during acute and recurring 
colitis and CAC in the dextran sulfate sodium (DSS) and azoxymethane + DSS models. Mice 
lacking the inflammasome adaptor protein PYCARD (ASC) and caspase-1 demonstrate 
increased disease outcome, morbidity, histopathology, and polyp formation. The increased 
tumor burden is correlated with attenuated levels of IL-1 and IL-18 at the tumor site.  
To decipher the nucleotide-binding domain, leucine-rich-repeat-containing (NLR) compo-
nent that is involved in colitis and CAC, we assessed Nlrp3 and Nlrc4 deficient mice. 
Nlrp3/ mice showed an increase in acute and recurring colitis and CAC, although the 
disease outcome was less severe in Nlrp3/ mice than in Pycard/ or Casp1/ animals. 
No significant differences were observed in disease progression or outcome in Nlrc4/ 
mice compared with similarly treated wild-type animals. Bone marrow reconstitution 
experiments show that Nlrp3 gene expression and function in hematopoietic cells, rather 
than intestinal epithelial cells or stromal cells, is responsible for protection against  
increased tumorigenesis. These data suggest that the inflammasome functions as an  
attenuator of colitis and CAC.
© 2010 Allen et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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and leads to the processing of procaspase­1 into caspase­1 
(Agostini et al., 2004). Caspase­1 is responsible for the subse­
quent cleavage of the IL­1/IL­18 precursor into their func­
tional forms. In addition to NLRP3, other NLRs, including 
NLRP1, NLRC4, and NAIP, also function in caspase­1   
activation and IL­1 production through the formation of 
other inflammasomes in response to distinct sets of stimuli 
(Mariathasan et al., 2004).
Although studies in humans and mice have found a sig­
nificant role for IL­1 in tumorigenesis, the roles of the   
inflammasome components have not been studied. In this 
study, we show that components of the inflammasome have 
a profound protective influence on colitis and colitis­associ­
ated cancer (CAC). This study is the first to address the 
role of NLR inflammasomes in CAC and demonstrates a 
protective role for PYCARD, caspase­1, and NLRP3 against 
CAC development.
RESULTS
NLR inflammasome components attenuate acute  
and recurring gastrointestinal inflammation during 
experimentally induced colitis
We first sought to assess the role of the NLRP3 inflamma­
some in acute and recurring models of gastrointestinal in­
flammation,  without  the  confounding  effects  of  tumor 
development. The dextran sulfate sodium (DSS) model has 
been shown to recapitulate many of the clinical observations 
associated with UC in humans (Neufert et al., 2007). In the 
acute model, mice were challenged with 5% DSS for 6 d and 
survival was assessed for 14 d (Fig. 1 A). Under these conditions, 
fungi, and viruses, as well as damage­associated molecular 
patterns (DAMPs), including uric acid, alum salt, silica, and 
reactive oxygen species (Cassel et al., 2009). Among the TLR 
family, various members (TLR2, TLR4, TLR5, and TLR9) 
and their adaptor protein MyD88 have been shown to be 
involved in innate immune signaling pathways associated 
with gastrointestinal inflammation and tumorigenesis in both   
humans and mice (Fukata and Abreu, 2009). Similar to the 
TLRs, members of the NLR family have also been impli­
cated as modulators of gastrointestinal inflammation, includ­
ing NOD2, which is the prototypical NLR associated with 
IBD (Ogura et al., 2001). However, the vast majority of 
NLR family members have yet to be assessed in models of 
gastrointestinal inflammation and tumorigenesis.
The processing and release of proinflammatory cytokines 
and chemokines, including IL­1 and IL­18, is fundamental 
to proper innate immune responses to pathogens and envi­
ronmental insults in the gastrointestinal system. Genetic asso­
ciation studies showed that polymorphisms in the IL­1 gene 
cluster significantly increase the risk of developing a variety 
of cancers, including gastric cancer (Barber et al., 2000;   
El­Omar et al., 2001). IL­1 levels are significantly altered in 
patients suffering from either acute or chronic gastrointestinal 
inflammation and have been implicated in tumor angiogene­
sis, progression, and metastasis (Bioque et al., 1995; Casini­
Raggi et al., 1995). In many circumstances, IL­1 and IL­18 
processing is dependent on the NLR protein, NLRP3, which 
associates with the NLR adapter protein, Apoptotic Speck 
protein containing a CARD (ASC/PYCARD), to recruit 
procaspase­1. This complex is referred to as the inflammasome, 
Figure 1.  NLR inflammasome components attenuate acute ulcerative colitis. (A) Schematic of the acute model of DSS-induced ulcerative colitis. 
(B) Kaplan-Meier plot of WT, Nlrp3/, Pycard/, and Casp1/ mouse survival. (C) Weight loss of WT, Nlrp3/, and Pycard/ mice. (D) Clinical param-
eters (weight loss, stool consistency, bleeding) of indicated mice. Data shown are representative of at least three independent experiments and depict the 
mean ± SEM. The symbols # and § indicate P < 0.05 and P < 0.01, respectively, between the mock- and DSS-treated WT; * indicates P < 0.05 between the 
DSS-treated gene-deficient strains compared with DSS-treated WT. WT mock, n = 4; DSS-treated WT, n = 14; Pycard/, n = 4; Nlrp3/, n = 6; Casp1/, 
n = 4. Casp1/ animals were highly sensitive to the acute administration of DSS and were not subjected to additional monitoring described in C and D 
for humane reasons.JEM VOL. 207, May 10, 2010 
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the  overall  HAI  score  compared  with  mock­treated  WT 
mice (Fig. 2 G). No significant differences in histopathology 
were observed between the DSS­treated WT and Nlrp3/ 
mice; however, Pycard/ and Casp1/ animals demon­
strated significantly increased HAI scores compared with the 
other genotypes (Fig. 2 G). Characterization of the individual 
HAI components including inflammation, epithelial defects, 
crypt atrophy, and area involved in disease is depicted in   
Fig. S1 (B–E). These data indicate a stronger protective role 
of PYCARD and caspase­1 than NLRP3 in recurring colitis. 
Together, these data suggest that inflammasome components 
attenuate both acute and recurring models of colitis. Because 
of the ultimate interest in colitis­associated tumorigenesis, we 
restricted the rest of this study to the recurring colitis model.
The inflammasome adaptor protein PYCARD and caspase-1 
are required for tumor reduction in CAC
We next sought to assess the role of both PYCARD and 
caspase­1 in the development of inflammation­driven colon   
tumorigenesis. In humans, CRC can develop either sponta­
neously or as a complication of IBD. Of the chemical carcin­
ogens used in rodent CRC models, the majority of studies 
have used azoxymethane (AOM). Although AOM alone ex­
erts  colonotropic  carcinogenicity,  inflammation­dependent 
tumor  development  can  be  assessed  by  combining  AOM 
with the UC model (Neufert et al., 2007).
To evaluate the role of NLR inflammasomes in the initi­
ation and progression of CAC, Pycard/, and Casp1/ mice 
were subjected to an AOM/DSS recurring inflammation­
driven colon tumorigenesis model. This model differs from 
the recurring colitis model in that the carcinogen AOM is 
given before DSS treatment (Fig. 3 A; Neufert et al., 2007). 
No overt phenotype, spontaneous gastrointestinal inflamma­
tion or tumorigenesis has been reported by others, nor ob­
served by us, in naive Pycard/, Casp1/, and Nlrp3/ 
animals. After AOM and the completion of the first two DSS 
challenges, a dramatic increase in the number of moribund 
Casp1/ and Pycard/ mice was observed compared with 
similarly treated WT animals (Fig. 3 B). The moribund 
Casp1/ (87.5%) and Pycard/ (77.8%) mice were hu­
manely euthanized between days 29 and 46. As in the experi­
mental colitis model, weight loss was assessed at least five 
times per week throughout the inflammation­driven colon 
tumorigenesis model. The majority of Casp1/ animals 
demonstrated significantly increased sensitivity to repeated 
challenges with DSS, with a drastic decrease in body weight 
(range, 15.7 to 42.7%) observed after the completion of 
two rounds of treatment (Fig. 3 C). Pycard/ mice demon­
strated significantly increased weight loss starting from day 
15, which lasted through the duration of treatment (Day 
29 = 16.10 ± 5.64%) compared with the WT animals (Day 
29 = 0.89 ± 1.54; Fig. 3 D). The majority of Casp1/ and 
Pycard/ mice required euthanasia for humane reasons be­
tween days 29 and 38. Hence, no additional weight loss data 
were  collected  for  these  animals  beyond  the  time  points 
shown. Consistent with changes in mortality and morbidity, 
the Casp1/ and Pycard/ mice demonstrated a significant 
decrease in survival, with all animals requiring euthanasia by 
days 9 and 11, respectively (Fig. 1 B). Although not as dra­
matic as the Casp1/ and Pycard/ mortality data, a signifi­
cant decrease in survival was also observed for Nlrp3/ mice 
compared with the WT mice (Fig. 1 B). It should be noted 
that mice deficient in caspase­1 demonstrated a very severe 
phenotype in the acute colitis model and additional experi­
ments were required to be halted because of humane reasons. 
Weight loss is typically considered a surrogate marker of 
morbidity and was assessed throughout the course of the DSS 
model. Consistent with the mortality data, the Nlrp3/ and 
Pycard/ mice demonstrated significant weight loss com­
pared with the WT animals (Fig. 1 C). Moribund mice were 
euthanized at day 9. The clinical score was measured using a 
semiquantitative scoring system designed to evaluate the hall­
mark features of gastrointestinal disease in mice (weight loss, 
stool consistency, and rectal bleeding; Siegmund et al., 2001). 
Consistent with increased morbidity and mortality, Pycard/ 
and Nlrp3/ mice presented with clinical features associated 
with enhanced gastrointestinal disease (Fig. 1 D). Together, 
these data suggest a protective role for both Pycard and Nlrp3 
in acute colitis induced by DSS.
We next assessed the roles of Pycard, Casp1, and Nlrp3 in 
a recurring colitis model. These mice were subjected to three 
rounds of DSS treatment (2.5%) over the course of 60 d   
(Fig. 2 A; Neufert et al., 2007). After the completion of the 
recurring  model,  Pycard/  Casp1/  and  Nlrp3/  mice 
showed increased inflammation and gastrointestinal disease, 
although the Nlrp3/ mice had a more subtle disease. In­
creased weight loss was observed in all DSS­treated mice, but 
after the first round of DSS treatment (between days 8 and 
10), Pycard/ (10.9%) and Nlrp3/ (9.0%) animals ex­
hibited more severe weight loss than WT controls (2.3%; 
Figs. 2, B and C). Both strains recovered after this initial de­
crease, and no other significant differences in weight loss 
were observed during subsequent DSS administrations. How­
ever, similar to the findings of the acute colitis study, Casp1/ 
animals were also highly sensitive to the recurring colitis 
model, with the majority requiring euthanasia by day 41   
(Fig. 2 D). All DSS­challenged mice presented with signifi­
cantly increased features of gastrointestinal disease, but Pycard/, 
Casp1/, and Nlrp3/ mice demonstrated significantly 
elevated clinical scores (0.67, 0.83, and 0.73, respectively) 
compared with the WT animals (0.22; Fig. 2 E). As an addi­
tional assessment of disease status, colon length was used to 
correlate with disease severity. Truncated colons were ob­
served in all DSS­treated mice, but colons harvested from 
Pycard/ (6.1 cm) and Casp1/ (6.4 cm) mice showed sig­
nificant truncation compared with the WT (7.7 cm) or Nlrp3/ 
mice (7.8 cm; Fig. 2 F and Fig. S1 A).
In the UC model, the Histological Activity Index (HAI) 
is a composite score based on individual scores of inflamma­
tion, epithelial defects, crypt atrophy, and the area involved 
in disease in the mid and distal colon (Meira et al., 2008). All 
DSS­treated animals demonstrated a significant increase in 1048 NLRP3 suppresses colitis-associated cancer | Allen et al.
that many of these masses were adeno­
carcinomas.  All  animals  challenged 
with AOM/DSS also demonstrated a 
significant increase in colon histopa­
thology (Fig. 3 G) with Pycard/ and 
Casp1/ mice exhibiting a significant 
increase in HAI compared with simi­
larly treated WT animals. In the CAC 
model, the composite HAI is calculated 
as described for colitis alone, but also 
includes assessments of mid and distal colon hyperplasia and 
dysplasia (Meira et al., 2008). The scores of the individual HAI 
components are shown in Fig. S2. Increased inflammation, 
epithelial defects, disease area, and crypt atrophy was observed 
in the mid and distal colons from both Pycard/ and Casp1/ 
mice (Fig. S2, A–D). Significantly increased distal colon hyper­
plasia and dysplasia were observed in Pycard/ and Casp1/ 
mice compared with similarly treated WT animals (Fig. S2, 
E–F). Pycard/ and Casp1/ mice also show an increase in 
mid­colon hyperplasia and dysplasia compared with WT con­
trols, but this increase was not statistically significant. These data 
demonstrate that the inflammasome components, PYCARD 
and caspase­1, function to attenuate inflammation and hyper­
plasia/dysplasia  in  the  inflammation­driven  colon  tumori­
genesis model.
Casp1/  and  Pycard/  mice  demonstrate  significantly 
increased clinical scores associated with enhanced gastrointes­
tinal disease (Fig. 3 E). These clinical data suggest that PY­
CARD and caspase­1 are necessary for mouse survival and 
serve a protective role during inflammation­driven colon tu­
morigenesis. The rapid progression to a moribund state ob­
served in the Pycard/ and Casp1/ mice upon AOM/DSS 
treatment suggests an increased pathological condition. In vivo 
tumorigenesis  was  evaluated  by  a  gastroenterologist  during 
week  6  of  the  AOM/DSS  model  in  WT,  Pycard/,  and 
Casp1/ mice via high­resolution endoscopy. All AOM/DSS­
challenged animals demonstrated increased colon inflammation 
compared with mock­treated mice. Increased numbers of poly­
ploidy masses were identified in the colons of Casp1/ and 
Pycard/ mice (Fig. 3 F). Histopathological analysis revealed 
Figure 2.  NLR inflammasome compo-
nents attenuate recurring ulcerative coli-
tis. (A) Schematic of the recurring model of 
DSS-induced ulcerative colitis. (B–D) Weight 
loss of Pycard/, Nlrp3/, and Casp1/ 
mice after DSS challenge. (E) Clinical param-
eters (weight loss, stool consistency, and 
bleeding) of indicated mice. These data are 
the averages of each clinical score collected 
throughout the recurring colitis model.  
(F) Colon length of indicated mice. (G) Colon 
histopathology scores reflecting the severity 
of inflammation, epithelial defects, crypt atro-
phy, and area affected in hematoxylin and 
eosin–stained sections through the mid and 
distal colon. The individual scores are shown 
in Fig. S2 and summed to generate a HAI. 
Colon length and histopathology were as-
sessed in the Casp1/ animals on day 40, 
whereas these two parameters were assessed 
on day 57 in the other genotypes tested. Data 
shown are representative of three indepen-
dent experiments and depict the mean ± SEM. 
Error bars have been omitted from the weight 
loss data for clarity of presentation. The sym-
bols # and § indicate P < 0.05 and P < 0.01, 
respectively, between the mock- and DSS-
treated WT; * indicates P < 0.05 between the 
DSS-treated gene-deficient strains and WT. 
WT mock, n = 5; WT, n = 5; Pycard/, n = 3; 
Casp1/, n = 4; Nlrp3/, n = 3.JEM VOL. 207, May 10, 2010 
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in the organ cultures from Pycard/ 
and Casp1/ animals (Fig. 4, A–B). 
This  is  consistent  with  the  roles  of 
PYCARD and caspase­1 in inflamma­
some processing of IL­1 and IL­18. 
We also observed a decrease in TNF 
levels in the Pycard/ mice compared 
with WT (Fig. 4 C). This reduction in TNF is likely caused by 
an inflammasome­independent role for PYCARD in the reg­
ulation of TNF (Taxman et al., 2006). These data confirm that 
PYCARD and caspase­1 are required for the production of IL­
1 and IL­18 in the inflammation­driven colon tumorigenesis 
model. The increased inflammation and tumor burden ob­
served in the Pycard/ and Casp1/ animals is correlated 
with a measurable loss of function of these two genes.
NLRP3 attenuates the development of gastrointestinal 
disease in CAC
PYCARD and caspase­1 are both required for the proper 
functioning of the majority of characterized NLR inflam­
masomes. If the phenotypes that we have described for   
the Pycard/ and Casp1/ mice are NLR dependent, we 
would predict that loss of a specific NLR would recapitulate 
IL-1 and IL-18 levels are attenuated in colons  
isolated from Pycard/ and Casp1/ mice after  
the induction of CAC
PYCARD and caspase­1 are required for NLR­ and absence 
in melanoma 2 (AIM2)–dependent inflammasome processing 
of IL­1 and IL­18. In addition, each is known to have in­
flammasome­independent  activities  in  regulating  distinct   
aspects of cell death (Miura et al., 1993; Masumoto et al., 
1999). To measure proinflammatory cytokine levels in the 
colons, organ cultures were established from mice that had 
completed the recurring colitis tumorigenesis model. Organ 
culture supernatants were harvested after incubation for 24 h 
and  IL­1,  IL­18,  and  TNF  levels  were  determined  by 
ELISA. Treatment with AOM and DSS caused a significant 
increase in proinflammatory cytokine levels in the WT mice 
(Fig. 4). IL­1 and IL­18 levels were significantly attenuated 
Figure 3.  Casp1/ and Pycard/ mice 
are highly susceptible to inflammation-
driven colon tumorigenesis. (A) Schematic 
of the four stage model of inflammation-
driven tumor progression using the chemical 
carcinogen AOM and DSS. (B) Kaplan-Meier 
plot of WT, Casp1/, and Pycard/ mouse 
survival. (C and D) Weight loss after 
AOM+DSS challenge. (E) Clinical parameters 
associated with increased gastrointestinal 
disease. (F) Inflammation and tumors revealed 
by in vivo high resolution endoscopy of dur-
ing week 6 of the recurring colitis-driven 
tumor model. Asterisks indicate large tumors 
throughout the distal colons. (G) Colon histo-
pathology scores reveal the severity of in-
flammation, epithelial defects, crypt atrophy, 
dysplasia, hyperplasia, and area affected in 
hematoxylin and eosin–stained sections 
through the mid and distal colon shown, as in 
Fig. S3. These scores were summed together 
to generate a HAI. Data shown are represen-
tative of three independent experiments and 
depict the mean ± SEM. Error bars have been 
omitted from the weight loss data for clarity 
of presentation. The symbol # indicates  
P < 0.05 between the AOM/mock and AOM/
DSS-treated WT; * indicates P < 0.05 between 
the gene-deficient strains and WT. For the 
survival study: WT AOM/mock, n = 6; 
Casp1/ n = 8; Pycard/ n = 9; WT n = 9. 
For all other datasets: WT AOM, n = 3; WT,  
n = 9; Pycard/, n = 6; Casp1/, n = 3.1050 NLRP3 suppresses colitis-associated cancer | Allen et al.
effects are reduced compared with those observed for Pycard/ 
and Casp1/ mice.
NLRP3 deficiency enhances gastrointestinal tumorigenesis
To investigate the role of NLRP3 in tumor formation, we 
initially examined polyp formation via high­resolution endos­
copy at the 6 wk time point. This corresponds with the time 
point associated with increased polyploidy masses in the Py-
card/ and Casp1/ mice (Fig. 3). All AOM/DSS­treated 
animals demonstrated increased colon inflammation compared 
with mock­treated mice; however, no tumors were observed 
via endoscopy in the Nlrp3/, Nlrc4/, or WT colons at this 
time point (Fig. 6 A). However, extensive ulcerated sections 
of colon and fibrinogen deposition were identified in Nlrp3/ 
mice (Fig. 6 A). These highly abnormal ulcerated sections of 
colon are indicative of precancerous lesions, thus leading us to 
examine if Nlrp3/ mice would develop increased tumori­
genesis during later stages of the CAC model.
Upon completion of the CAC model (week 9), macro­
scopic colon polyps were detected in the majority of AOM/
DSS­treated mice (Fig. 6 B). However, a dramatic increase in 
the mean number of polyps was observed in the colons of 
Nlrp3/ mice (4.5 ± 0.95) compared with those isolated 
from the WT (1 ± 0.45) or Nlrc4/ animals (0.57 ± 0.30; 
Fig. 6 B). In addition to greater frequencies, these polyps 
were also much larger in both maximal cross­sectional area 
and wet weight compared with the polyps isolated from WT 
mice (Fig. 6 C). Colon histopathology revealed a significant 
increase in the HAI score from all AOM/DSS­treated ani­
mals when compared with AOM/mock­treated WT mice. 
Increased HAI scores were observed for Nlrp3/ mice com­
pared with WT and Nlrc4/ animals (Fig. 6 D). However, 
when compared with the HAI of similarly treated Pycard/ 
(27.33 ± 0.54) and Casp1/ mice (24.00 ± 1.00) shown 
earlier (Fig. 3 G), the HAI for the Nlrp3/ mice (19.00 ± 
1.39) was significantly reduced (Fig. 6 D). These findings are 
consistent with the attenuated and slower disease progression 
observed in the Nlrp3/ animals compared with the rapid 
disease progression found in Pycard/ and Casp1/ mice. 
As expected by the increase in polyp number, a significant 
increase in distal colon hyperplasia, dysplasia, and area in­
volved with pathology was observed in the Nlrp3/ mice 
compared with similarly treated WT and Nlrc4/ animals 
(Figs. 6, E–G). In contrast to the findings for the Pycard/ 
and Casp1/ mice, inflammation and midcolon disease pa­
rameters were similar between the WT, Nlrc4/, and Nlrp3/ 
animals (Fig. S3). These data indicate that Nlrp3/ mice ex­
hibit an attenuated disease when compared with Pycard/ 
and Casp1/ mice; however, the composite data support the 
hypothesis that this gene product negatively regulates tumori­
genesis in the CAC model.
NLRP3 mediates gastrointestinal disease through 
hematopoietic-derived cells
We next sought to establish the relevant cell compartment of 
the host that is responsible for the increased susceptibility to 
the observed phenotypes. NLRP3 can form an inflamma­
some complex with PYCARD and caspase­1 in response 
to a diverse range of environmental stressors and DAMPs 
(Martinon et al., 2006; Sutterwala et al., 2006; Eisenbarth 
et al., 2008; Li et al., 2008). Common variants in the NLRP3 
regulatory region have been shown to alter colonic NLRP3 
expression, IL­1 production and are associated with increased 
susceptibility to Crohn’s disease (Villani et al., 2009). In ad­
dition to NLRP3, other NLRs, such as NLRC4, can form 
NLRP3­independent inflammasome in response to specific 
stimuli, such as flagellin (Mariathasan et al., 2004).
To determine the role of a specific NLR inflammasome, 
mice lacking either NLRP3 or NLRC4 were assessed in the 
inflammation­driven colon tumorigenesis model (Fig. 5 A). 
Unlike the survival phenotypes observed in the Pycard/ 
and Casp1/ mice, Nlrp3/ or Nlrc4/ animals did not 
progress to a moribund state requiring euthanasia (Fig. 5, 
B and C). Nlrp3/ mice exhibited a significant weight loss 
(Fig.  5  B)  but  the  loss  was  attenuated  compared  with   
Pycard/ and Casp1/ animals shown earlier. Increased 
weight loss was also observed in Nlrc4/ mice after the   
final treatment of DSS (Fig. 5 C). However, the change 
was highly variable and was not a statistically significant 
difference compared with similarly treated WT animals. 
Consistent with the weight loss phenotype, Nlrp3/ mice 
demonstrate a significant increase in clinical scores associ­
ated with gastrointestinal disease compared with WT and 
Nlrc4/ animals (Fig. 5 D). They also exhibited signifi­
cantly truncated colons compared with WT controls (Fig. 
5 E). Gross morphological differences including extensive 
truncation, wall thickening, and hemorrhaging were also 
observed in the majority of colons harvested from Nlrp3/ 
mice compared with WT controls (Fig. 5 F). These data 
indicate that Nlrp3, but not Nlrc4, attenuates morbidity 
and clinical outcome associated with CAC, although the 
Figure 4.  Reduced IL-1 and IL-18 production in colons isolated 
from Pycard and caspase-1 deficient mice. Colons isolated from the 
indicated AOM+DSS-challenged mice were cultured overnight and IL-1 
(A), IL-18 (B), and TNF (C) in the supernatants was measured by ELISA. 
Data shown are representative of at least three independent experiments 
and depict the mean ± SEM. The symbol # indicates P < 0.05 between the 
AOM/mock and AOM/DSS-treated WT; * indicates P < 0.05 between the 
gene-deficient strains and WT. AOM/mock, n = 3; WT, n = 6; Pycard/,  
n = 3; Casp1/, n = 3.JEM VOL. 207, May 10, 2010 
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attributed to the radiation and hema­
topoietic reconstitution process, none­
theless in both experimental designs, 
Nlrp3/  mice  showed  significantly 
more weight loss than WT. Nlrp3/ animals that received 
WT bone marrow demonstrate significantly less weight loss 
compared with Nlrp3/ mice and WT animals that received 
Nlrp3/ bone marrow. This indicates that the source of 
the hematopoietic compartment determines the outcome of 
weight loss. Consistent with the weight loss data, animals re­
ceiving Nlrp3/ bone marrow demonstrated significantly in­
creased clinical scores compared with mice receiving WT bone 
marrow (Fig. 7 C). Recipients of Nlrp3/ bone marrow also 
demonstrate truncated colons compared with animals trans­
planted with WT bone marrow (Fig. 7 D). These clinical data 
suggest that the phenotype observed in the Nlrp3/ mice is 
associated with hematopoietic­derived cells rather than the in­
testinal epithelial cells, tumor­derived cells, or stroma.
To extend the clinical findings, tumorigenesis, and in­
flammation was characterized in the chimeric mice harvested 
2 wk after the completion of the third round of DSS in the 
CAC model. Mice receiving Nlrp3/ but not WT bone 
marrow also demonstrated significantly increased colonic le­
sions (Fig. 7 E), including increased distal colon inflamma­
tion, hyperplasia, dysplasia, and area associated with disease 
(Fig. S4, A–F). Similar to Nlrp3/ animals, recipients of 
Nlrp3/ bone marrow exhibited an increase in the number 
of colonic macroscopic polyps (Fig. 7 F). Together, the clini­
cal and histopathology data indicate that NLRP3 regulates 
gastrointestinal tumorigenesis through hematopoietic­derived 
cells in models of CAC.
CAC in the Nlrp3/ mice. The intestinal epithelial cells and 
stroma  play  a  critical  role  in  gastrointestinal  biology  by   
providing the physical separation between the gut microflora 
and the cells of the mucosal immune system. Gut micro­
flora is believed to provide the carcinogenic metabolism of   
hydroxylated AOM that enables its colonotropic mutagenic­
ity within the intestinal epithelial cells in the AOM model 
(Reddy et al., 1974). Additional data suggest that hematopoi­
etic cells including macrophages and other myeloid­derived 
cells also play important but divergent roles in regulating   
colonic tumor initiation, growth, and metastasis (Biswas   
et al., 2008).
To determine the cellular compartment responsible for 
the phenotype observed in the Nlrp3/ mice, we generated 
chimeric animals by adoptive bone marrow transplantation, 
and then subjected the mice to the AOM/DSS colon tumor­
igenesis model (Fig. 7 A). As seen in Fig. 7 B, WT­irradiated 
recipients that received WT bone marrow did not demon­
strate  substantial  weight  loss  during  the  recurring  colitis 
model, whereas Nlrp3/ recipients of Nlrp3/ bone mar­
row experienced a significant decrease in weight, indicating 
that the bone marrow chimerization procedure did not alter 
the more significant weight loss observed in the Nlrp3/ 
mice. However, the pattern of weight loss in bone marrow 
chimeras occurred during the first two rounds of DSS treat­
ment rather than the latter two rounds, as observed with un­
irradiated  animals  (Fig.  5  B).  These  differences  might  be 
Figure 5.  Loss of Nlrp3 results in aug-
mented features of ulcerative colitis in 
the inflammation-driven tumor model.  
(A) Schematic of the CAC model using the 
chemical carcinogen AOM and DSS.  
(B and C) Weight loss measured throughout 
the colitis driven tumor progression model in 
WT, Nlrp3/, and Nlrc4/ mice (difference 
observed during the final week of study in C is 
not statistically significant). (D) Clinical scores 
reflecting weight loss, loose stool consistency, 
and amounts of blood present in stool and 
rectum. (E) Colon length. (F) Gross morphol-
ogy revealing areas of excessive wall thicken-
ing and hemorrhage. Data shown are 
representative of 3 independent experiments 
and depict the mean ± SEM. Error bars have 
been omitted from the weight loss data for 
clarity of presentation. The symbols # and § 
indicate P < 0.05 and P < 0.01, respectively, 
between the AOM/mock and AOM/DSS-
treated WT; * indicates P < 0.05 between the 
Nlrp3/ and WT mice. WT, n = 15; Nlrp3/, 
n = 12; Nlrc4/, n = 4; WT AOM/mock, n = 3.1052 NLRP3 suppresses colitis-associated cancer | Allen et al.
is associated with reduced inflamma­
some function at the tumor site.
Our data show that the NLR in­
flammasome components PYCARD, 
caspase­1,  and  NLRP3  might  func­
tion as inflammation and tumor sup­
pressors  in  the  inflammation­driven 
colon tumorigenesis model. Pycard/ 
and Casp1/ mice have significantly 
attenuated NLR inflammasome activ­
ity. Despite reduced levels of proin­
flammatory IL­1 and IL­18 within 
the site of polyp formation, both sets 
of genetically altered mice developed 
increased areas of local inflammation 
and enhanced dysplasia and hyper­
plasia.  It  should  be  noted  that  our 
data present a correlative link between 
the dysregulation of IL­1 and IL­18 
and the development of gastrointesti­
nal disease; however, it is still unclear if this dysregulation is 
directly related to the increase in colitis and colitis­associated 
tumorigenesis. One possible explanation of enhanced tumor­
igenesis observed in the Pycard/ and Casp1/ mice can be 
attributed to their previously defined roles associated with 
programmed cell death. Pycard was originally found to in­
crease the susceptibility of leukemia cell lines to apoptotic 
stimuli associated with anticancer drugs (Masumoto et al., 
1999).  Likewise,  caspase­1–mediated  cell  death  has  been 
shown to be suppressed by BCL2 overexpression (Miura et al., 
1993). An alternative explanation is that the increased suscep­
tibility of these mice to CAC may be caused by the loss of 
downstream signaling mediated by the respective receptors 
for either IL­1 or IL­18. For example, MyD88 is involved 
in  IL­1  and  IL­18  receptor  signaling.  Other  investigators 
have previously shown that MyD88 and TLR signaling can 
maintain homeostasis and protect the intestine upon DSS­
induced or bacteria­induced colitis, partly by the recognition 
DISCUSSION
A current dogma in cancer immunology suggests that inflam­
mation functions as a tumor promoter. Components of the 
inflammasome  function  to  process  pro–IL­1  and  –IL­18 
into mature cytokines, thus an initial hypothesis centered on 
the concept that increased inflammation caused by inflamma­
some formation creates a local environment that is favorable 
for tumorigenesis. This hypothesis predicts reduced inflam­
mation and attenuated tumorigenesis in mice lacking NLR 
inflammasome  components.  However,  the  data  presented 
throughout this study, have led us to propose a protective 
role for the inflammasome during chronic colitis and coli­
tis­associated colon cancer. These results parallel other find­
ings in the literature that suggest that other innate immune 
sensors, such as MyD88, can serve as a protective and ho­
meostatic factor in the intestine (Araki et al., 2005). In our 
work, we also find that deficiencies in diverse inflammasome 
components can lead to enhanced colitis, as well as CAC that 
Figure 6.  NLRP3 mediates gastrointesti-
nal tumorigenesis in the CAC model.  
(A) Endoscopic analysis of mice during week 6 
of the recurring CAC model. (B) Macroscopic 
polyps were quantified in indicated mice.  
(C) Size and weight of representative macro-
scopic polyps from indicated mice. (D) Com-
posite HAI scores. (E–G) Distal colon 
hyperplasia (E), dysplasia (F), and area involved 
with disease (G). Data are representative of 
three independent experiments. The symbol # 
indicates P < 0.05 between the AOM/mock 
and AOM/DSS-treated WT; * and ** indicate  
P < 0.05 and P < 0.01, respectively, between 
the Nlrp3/ and WT mice. WT AOM, n = 3; WT, 
n = 10; Nlrc4/, n = 3; Nlrp3/, n = 6.JEM VOL. 207, May 10, 2010 
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colitis. Likewise, colitis models can be 
significantly influenced by several vari­
ables that are unique to each specific 
institution including: differences in the 
gastrointestinal microflora between the   
various  animal  facilities,  differences 
in the type of water (deionized, au­
toclaved,  or  tap)  used  to  administer 
the DSS, and differences in the con­
centration and duration of administra­
tion of the DSS treatments. We have 
attempted to minimize these variables 
using  both  physical  mechanisms  (i.e., 
housing all of our animals in the same 
building/same room under SPF con­
ditions, making fresh DSS each day, using the same type of 
water for all experiments, and using only male mice) and us­
ing a standardized, published protocol for the DSS and 
AOM/DSS models (Neufert et al., 2007).
Our  data  show  that  the  inflammasome  component 
NLRP3 also plays a role in reducing acute colitis and colitis­
associated colon cancer. However, the modulating effect of 
NLRP3 on colon cancer is both attenuated and delayed dur­
ing CAC development compared with the roles played by 
PYCARD and caspase­1. This suggests that other NLR or 
non­NLR inflammasome components could contribute to 
the development of CAC. Although NLRP3 and NLRC4 
are the most extensively characterized NLRs that mediate 
inflammasome formation, NLRC4 does not have a signifi­
cant role in CAC. We chose to assess NLRC4 because of its 
well characterized role in forming an inflammasome in response 
to flagellated gastrointestinal pathogens such as Salmonella 
and Shigella (Lamkanfi and Dixit, 2009). In addition to the 
NLRs, the recently described AIM2 gene is of particular in­
terest because it is reduced or absent in several cancers and 
its restoration caused cell cycle arrest in colon cancer cell 
types (Patsos et al., 2010). AIM2 has been shown to form 
of commensal normal flora in the intestine (Rakoff­Nahoum 
et al., 2004; Araki et al., 2005; Fukata et al., 2005). How­
ever, in several cases of spontaneous or chemical­induced 
colitis, MyD88 has been found to act as a tumor promoter. In 
an AOM­exposed, Il10/ mouse model, MyD88 is required 
for  the  development  of  neoplastic  lesions  (Uronis  et  al., 
2009). In a spontaneous tumor model caused by a mutation 
in the adenomatous polyposis coli gene, MyD88 exacerbated 
intestinal polyp development partly by reducing apoptosis 
(Rakoff­Nahoum and Medzhitov, 2007). In contrast to these 
findings, T-bet/, RAG2/ mice that exhibited spontane­
ous UC that progressed to adenocarcinoma did not involve 
MyD88 (Garrett et al., 2009). These findings suggest that the 
role of MyD88 in tumorigenesis is complex, and likely varies 
with genetic variations, tissue/cellular involvement, and timing 
of carcinogenic insult.
Our findings are also unexpected based on previously 
published findings on the role of caspase­1 in models of coli­
tis (Siegmund et al., 2001; Bauer et al., 2007). Several expla­
nations  are  possible  to  explain  the  observed  differences 
between the various studies. For example, mouse background 
and gender can have dramatic effects in the DSS model of 
Figure 7.  Mice receiving bone marrow 
from Nlrp3/ animals develop enhanced 
gastrointestinal disease. (A) Schematic of 
the four stage model of inflammation-driven 
tumor progression using the chemical  
carcinogen AOM in bone marrow chimeric 
mice. (B) Weight change of indicated BM chi-
meras. (C) Composite clinical scores reflecting 
weight loss, loose stool consistency, and blood 
in the stool and rectum. (D) Colon length.  
(E) Composite HAI scores. (F) Quantification of 
macroscopic polyps. Data depict the mean ± 
SEM and are representative of three indepen-
dent experiments. The symbol * indicates  
P < 0.05 in a comparison of the WT→WT 
control to the other three groups. WT→Nlrp3/, 
n = 7; Nlrp3/→WT, n = 7; WT→WT, n = 3; 
Nlrp3/→Nlrp3/, n = 3.1054 NLRP3 suppresses colitis-associated cancer | Allen et al.
proteins in mediating the host innate immune response to 
cancer will allow the generation of improved cancer thera­
peutics. As a cautionary note, our findings also suggest that 
when therapies targeting individual inflammasome compo­
nents become available, their unintended effects on CAC 
should be closely monitored.
MATERIALS AND METHODS
Experimental animals. All studies were approved by the Institutional 
Care and Use Committee of The University of North Carolina at Chapel 
Hill and were conducted in accordance with the IACUC guidelines and 
the National Institutes of Health Guide for the Care and Use of Labora­
tory Animals. The generation of mice lacking functional Nlrp3, Nlrc4, 
Pycard, and caspase­1 (Casp1) has been previously described (R. Flavell, 
Yale University, New Haven, CT; V. Dixit, Genentech, Inc., San Francisco, 
CA; F. Sutterwala, University of Iowa, Iowa City, IA; Adachi et al., 
1998; Mariathasan et al., 2004; Sutterwala et al., 2006). All experiments 
were conducted with age­matched male mice, and all mice were back­
crossed at least nine generations onto the C57BL/6. Mice were housed 
under  SPF  conditions  and  provided  5010  chow  (LabDiet)  and  water   
ad libitum.
Induction of colitis and inflammation-driven tumor progression. 
To assess the induction of acute colitis, all mice were subjected to one cycle 
of 5% DSS (MP Biomedicals) exposure as illustrated in Fig. 1 A. To assess the 
induction of recurring UC, mice were exposed to 3 cycles of 2.5% DSS as 
illustrated in Fig. 2 A (without the addition of AOM; Neufert et al., 2007). 
Mice were sacrificed and inflammation assessments made at specific time 
points throughout the course of the challenge. To evaluate tumorigenesis, 
mice received 1 i.p. injection (10 mg/kg body weight) of AOM (Sigma­ 
Aldrich) followed by 3 cycles of DSS treatments (2.5%; Fig. 3 A). Mice   
were sacrificed and tumor assessments made 10 wk after AOM injection or 
when moribund.
Body weight, the presence of rectal bleeding, and stool consistency 
were scored and averaged to generate a semiquantative clinical score as pre­
viously described (Siegmund et al., 2001). In brief, body weight and stool 
consistency were assessed at least 5 d per week throughout the course of the 
DSS exposure. Rectal bleeding was assessed 1 d and 4 d after each DSS treat­
ment by sampling for the presence of blood in the stool using a Hemoccult 
Immunochemical Fecal Occult Blood Test (Beckman Coulter). In addition 
to the composite clinical score, colon lengths were measured for each animal 
at the completion of each study.
Endoscopic tumor investigation. To evaluate tumor growth and pro­
gression in vivo, mice were anesthetized with isoflurane (Minrad, Inc.) and 
monitored by miniendoscopy, as previously described (Uronis et al., 2007). 
In brief, endoscopy was performed during week 6 of the UC and CAC 
models using a “Coloview system” (Karl Storz Veterinary Endoscope) and 
each session was digitally recorded. If fecal matter obstructed visualization, 
colons were flushed with 1X PBS. After air inflation, the colonoscopy   
allowed for the real­time evaluation of 3–4 cm of colon from the anal 
verge to the splenic flexure.
Macroscopic polyp analysis and histopathology. Upon harvest, the 
entire  colon  was  removed  (rectum  to  cecum),  flushed  to  remove  fecal   
matter, and opened longitudinally. Macroscopic polyps were identified by 
analysis  under  a  dissecting  microscope  (10×  magnification)  by  a  trained   
investigator, and the number and size of polyps were assessed in their maxi­
mum dimension.
For histopathology, the entire colon was removed, flushed with PBS, 
opened longitudinally, swiss rolled, and fixed in 10% buffered formalin. 
Subsequently, paraffin embedded samples were sectioned at 5 µm, stained 
with hematoxylin and eosin and evaluated by a trained veterinary pathol­
ogist, as previously described (Meira et al., 2008). In brief, sections were 
an NLRP3­independent inflammasome with Pycard and 
caspase­1 in response to cytoplasmic DNA, which then 
processes IL­1 and IL­18 (Bürckstümmer et al., 2009; 
Fernandes­Alnemri et al., 2009; Hornung et al., 2009). It will 
be interesting to test the role played by inflammasome com­
ponents such as AIM2 when mice lacking this gene be­
come available.
Based on the mechanism of action for DSS (initiating   
a wound­healing response in the colonic epithelial layer), 
it is our belief that the phenotypes we are observing in   
the Nlrp3/ mice are likely caused by an indirect mech­
anism. We attempted to directly activate the inflamma­
some  with  DSS  in  bone  marrow–derived  macrophages, 
and our initial analysis suggests that DSS does not directly 
induce the production of IL­1 (unpublished data). How­
ever,  damage  to  the  colonic  epithelial  cell  layer  in  the   
colon initiates the release of various DAMP signals, and 
DAMPs have the potential to activate the NLRP3 inflam­
masome. Thus, it is possible that a failure of the hemato­
poietic cells to recognize and effectively cope with these 
indirect signals results in the eventual development of in­
creased CAC.
Our  data  suggest  that  NLRP3  regulates  tumorigenesis 
through the hematopoietic/myeloid compartment. This find­
ing is consistent with the known biology of NLRP3 because 
the vast majority of NLRP3’s function can be attributed to its 
presence in myeloid­derived cells, specifically monocytes/
macrophages. Tumor­associated myeloid­derived cells dem­
onstrate a great deal of flexibility throughout the course of 
tumor progression. During conditions of chronic inflamma­
tion, such as IBD, macrophages can initiate tumorigenesis 
through the release of proinflammatory mediators and other 
factors that promote neoplastic transformation. Once a tumor 
becomes  established,  macrophages  and  myeloid­derived 
cells create a local environment which can be immunosup­
pressive and is thus favorable for tumor growth, angiogen­
esis, and metastasis. However, monocytes/macrophages are 
also involved in the antitumor response of the host by func­
tioning as cytotoxic effector cells, inducing reactive oxygen 
species and producing cytokines such as IL­12, which has anti­
proliferative, antiangiogenic, and cytotoxic effects through 
the subsequent generation of IFN­ (Nardin and Abastado, 
2008). In the gut, myeloid­derived cells also act as tumor­
associated antigen­presenting cells and are responsible for 
efficient phagocytosis and removal of apoptotic/tumorigenic 
cells (Zitvogel et al., 2006).
In summary, the two­hit model of inflammasome forma­
tion posits that IL­1/IL­18 processing requires a first hit 
that is mediated by signals such as TLR and MyD88 resulting 
in increased pro–IL­1/IL­18 transcription and a second hit 
that initiates the posttranslational processing of caspase­1,   
IL­1, and IL­18 proteins by the inflammasome components. 
The findings of this study suggest that both signals, emanating 
from two distinct classes of innate immune sensors, serve to 
attenuate colitis and CAC. Further understanding of the spe­
cific roles of the NLRs and inflammasome­associated adaptor JEM VOL. 207, May 10, 2010 
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scored blindly for inflammation, epithelial defects, crypt atrophy, hyper­
plasia, dysplasia/neoplasia, and area affected by dysplasia. Inflammation 
was determined based on the number and extent of leukocyte infiltration. 
Epithelial defects were determined based on the severity of damage to   
the epithelial cell layer. Crypt atrophy was scored based on visual esti­
mates of the percent of atrophy in the crypts of the most affected areas of 
colon. Hyperplasia and dysplasia were scored based on the severity of the 
cellular changes induced by disease and ranged from mild atypia to in­
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scribed (Greten et al., 2004). In brief, the colons were removed and cut open 
longitudinally. These strips were washed with PBS containing penicillin/
streptomycin,  the  distalmost  3  cm  were  isolated  and  further  cut  into   
1­cm2 sections, and the wet weight of each was recorded. Colon sections 
were covered with RPMI media, including penicillin/streptomycin, and   
incubated overnight. Cell­free supernatants were harvested and assayed via 
ELISA for IL­1, IL­18, and TNF.
Generation of chimeric mice by bone marrow reconstitution. To 
evaluate the hematopoietic cell contribution to the initiation and progression 
of tumorigenesis, chimeric mice were generated using bone marrow trans­
plantation following standard protocols. In brief, recipient mice were lethally 
irradiated (single dose of ­irradiation, 950 rad) and 12 h later the mice   
received 5 × 106 bone marrow cells flushed from the femurs and tibias of 
WT and Nlrp3/ mice. Bone marrow was harvested and prepared follow­
ing standard procedures. The bone marrow reconstitution was performed 
reciprocally, resulting in the generation of four groups of experimental mice. 
The surviving mice were subjected to the 4­stage AOM/DSS model, 6 wk 
after transplantation.
Statistical analysis. Data are presented as the mean ± SEM. Analysis of 
variance followed by either Tukey­Kramer HSD or Newman­Keuls Post 
Test for multiple comparisons was performed on complex datasets for both 
individual experiments and composite data. Statistical significance for single 
data points were assessed by the Student’s two­tailed t test. Survival curves 
were generated using the product limit method of Kaplan and Meier, and 
comparisons were made using the log­rank test. In all cases, a P value of 
>0.05 was considered statistically significant.
Online supplemental material. In Fig. S1, Pycard/ mice demonstrate 
increased mid and distal colon histopathology in the recurring ulcerative 
colitis model. In Fig. S2, Casp1/, and Pycard/ mice demonstrate in­
creased mid and distal colon histopathology in the CAC model. Fig. S3 
shows increased gastrointestinal disease was localized to the distal colon in 
the Nlrp3/ mice. Fig. S4 shows increased histopathology in mice receiving 
Nlrp3/ bone marrow. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20100050/DC1.
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